Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $38.60 $44.37 Friday, 10th May 2024 XENE stock ended at $40.54. This is 4.59% less than the trading day before Thursday, 9th May 2024. During the day the stock fluctuated 10.26% from a day low at $38.60 to a day high of $42.56.
90 days $38.60 $50.99
52 weeks $27.99 $50.99

Historical Xenon Pharmaceuticals Inc. prices

Date Open High Low Close Volume
Jan 24, 2024 $45.47 $45.47 $43.87 $44.03 279 430
Jan 23, 2024 $45.20 $45.52 $44.19 $45.05 296 887
Jan 22, 2024 $44.02 $45.38 $43.53 $45.20 458 447
Jan 19, 2024 $44.26 $44.34 $43.25 $43.77 274 366
Jan 18, 2024 $45.71 $45.77 $43.95 $44.10 391 755
Jan 17, 2024 $45.19 $45.69 $44.70 $45.63 595 901
Jan 16, 2024 $44.81 $45.84 $44.63 $45.83 491 255
Jan 12, 2024 $45.40 $45.70 $44.77 $45.09 365 132
Jan 11, 2024 $44.57 $45.62 $43.88 $44.92 567 057
Jan 10, 2024 $47.06 $47.63 $44.49 $45.08 432 843
Jan 09, 2024 $47.51 $47.98 $46.67 $47.15 695 664
Jan 08, 2024 $45.26 $48.00 $45.03 $47.88 741 774
Jan 05, 2024 $45.64 $46.03 $44.93 $45.50 581 087
Jan 04, 2024 $46.10 $46.98 $44.29 $46.02 1 197 604
Jan 03, 2024 $44.70 $44.91 $44.09 $44.19 285 066
Jan 02, 2024 $45.49 $46.17 $44.09 $44.91 638 357
Dec 29, 2023 $46.30 $46.61 $45.79 $46.06 595 091
Dec 28, 2023 $46.46 $47.00 $46.02 $46.30 799 156
Dec 27, 2023 $45.95 $46.67 $45.32 $46.46 508 179
Dec 26, 2023 $44.71 $45.81 $44.40 $45.80 664 124
Dec 22, 2023 $42.50 $45.40 $42.41 $44.63 1 484 503
Dec 21, 2023 $41.60 $41.90 $41.02 $41.53 379 621
Dec 20, 2023 $41.62 $41.79 $40.67 $41.00 450 521
Dec 19, 2023 $41.93 $42.60 $41.54 $42.01 443 678
Dec 18, 2023 $41.65 $42.16 $40.94 $41.15 453 738
Click to get the best stock tips daily for free!

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals. Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment o... XENE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT